Granuloma annulare is not formally classified as an autoimmune disease, but the immune system is deeply involved in causing it, and the line between “autoimmune” and “immune-mediated” is thinner here than in many other skin conditions. People with GA are significantly more likely to also have recognized autoimmune diseases like thyroiditis and lupus, and the molecular machinery driving GA lesions overlaps with pathways seen in classic autoimmune disorders. The honest answer is that GA sits in a gray zone, and the evidence increasingly tilts toward autoimmunity playing a real role in at least some forms of the disease.
What Happens Inside a GA Lesion
If you looked at a GA bump under a microscope, you would see clusters of immune cells, especially a type called histiocytes (tissue-dwelling immune cells from the macrophage family), arranged around zones of damaged collagen. This pattern of immune cells surrounding damaged tissue is the “granuloma” in granuloma annulare. Collagen breakdown was found in every single case in one study of 30 biopsies, and mucin, a gel-like substance produced during tissue inflammation, appeared in about 80% of cases.1PubMed Central. Evaluating the Unusual Histological Aspects of Granuloma Annulare: A Study of 30 Cases Some biopsies also showed signs of blood vessel inflammation and the presence of eosinophils, immune cells more commonly associated with allergic and autoimmune reactions.
The critical finding is that T cells, particularly CD4-positive helper T cells, are consistently present in GA lesions. One study analyzing biopsies from 11 patients found significant numbers of CD4 T cells in every case, along with elevated production of interleukin-2, a cytokine that amplifies immune responses.2PubMed. T-cell receptor repertoire and cytokine pattern in granuloma annulare: defining a particular type of cutaneous granulomatous inflammation These T cells did not show a narrow, antigen-specific profile the way you would expect if the immune system were targeting one specific invader. Instead, they used a broad range of receptors, suggesting the immune activation is more diffuse and potentially self-directed.
The Immune Pathways Driving GA
Recent molecular work has identified specific immune signaling programs active in GA skin. A spatial transcriptomics study found that IFN-γ, TNF, and a cytokine called IL-32 emerged as important regulators of the granulomatous inflammation in GA.3PubMed. Granuloma Annulare Exhibits Mixed Immune and Macrophage Polarization Profiles with Spatial Transcriptomics IFN-γ and TNF are the same inflammatory signals that drive tissue damage in classic autoimmune conditions like rheumatoid arthritis and Crohn’s disease.
Another molecular profiling study found that GA skin shows activation of both Th1 (inflammatory) and Th2 (allergic-type) immune pathways simultaneously, along with activation of JAK signaling, a pathway that has become a major drug target in autoimmune diseases.4Journal of the American Academy of Dermatology. Granuloma annulare skin profile shows activation of T-helper cell type 1, T-helper cell type 2, and Janus kinase pathways Research comparing GA to sarcoidosis, another granulomatous condition, confirmed that both diseases show constitutive activation of STAT1 and STAT3, though the specific patterns differ between the two.5PubMed Central. Janus kinase inhibition induces disease remission in cutaneous sarcoidosis and granuloma annulare The fact that GA activates the JAK-STAT pathway is significant because this pathway is central to how immune cells communicate and respond in autoimmune and inflammatory diseases across the body.
GA and Autoimmune Diseases Travel Together
One of the strongest pieces of circumstantial evidence linking GA to autoimmunity is that the two frequently coexist in the same patients. A large population-based study published in JAMA Dermatology compared over 5,000 GA patients to matched controls and found that people with GA were significantly more likely to have autoimmune conditions at baseline, and also more likely to develop new autoimmune conditions during follow-up. The same study found that about 21% of GA patients had diabetes compared to roughly 13% of controls, and hyperlipidemia was also more common in the GA group.6PubMed Central. Association of Granuloma Annulare With Type 2 Diabetes, Hyperlipidemia, Autoimmune Disorders, and Hematologic Malignant Neoplasms The researchers concluded that autoimmunity may be an important factor in the development of GA.
Case reports and small studies have described GA appearing alongside autoimmune thyroiditis, lupus, and rheumatoid arthritis. One case report documented a woman with disseminated GA who simultaneously had autoimmune thyroiditis and lichen sclerosus, another immune-mediated skin condition, and argued the combination was unlikely to be coincidental.7PubMed Central. Granuloma annulare, autoimmune thyroiditis, and lichen sclerosus in a woman: randomness or significant association? A separate study described three patients with generalized GA who tested positive for autoantibodies, including antinuclear antibodies and anti-thyroid stimulating hormone receptor antibodies.8PubMed. Association of generalized granuloma annulare with autoantibodies Autoantibodies are hallmarks of autoimmune disease, and finding them in GA patients strengthens the case that the immune system’s misdirected activity extends beyond the skin.
What Actually Triggers It
If GA has autoimmune features, something has to kick the immune system into that abnormal gear. A range of triggers have been identified, and they share a common thread: they all perturb the immune system in some way.
Infections are one documented trigger. A case report described interstitial GA appearing after Lyme disease, with the patient testing positive for antibodies to the Lyme-causing bacterium.9PubMed. Interstitial granuloma annulare triggered by Lyme disease The idea is that the immune response launched against an infection sometimes continues or redirects itself against the body’s own tissue even after the infection is controlled, a well-recognized mechanism in autoimmune disease called molecular mimicry or bystander activation.
Perhaps the most telling trigger is immune checkpoint inhibitor therapy. These cancer drugs, including pembrolizumab, nivolumab, and ipilimumab, work by releasing the brakes on T cells so they can attack tumors more aggressively. A case series described nine patients who developed biopsy-confirmed GA after starting checkpoint inhibitor therapy, with a median onset of about 24 weeks after treatment began.10PubMed Central. Granuloma annulare associated with immune checkpoint inhibitors The researchers concluded that enhanced T-cell-mediated immunity from checkpoint blockade may trigger GA development. This is a strong clue: drugs that intentionally rev up the adaptive immune system cause GA to appear, which is exactly what you would expect if GA were driven by misdirected immune activity.
Genetic Clues Point Toward Immune Susceptibility
There is evidence that some people are genetically predisposed to developing GA, and the genes involved are ones that regulate immune function. A study of 78 patients found that two specific immune-related gene variants, HLA-A31 and HLA-B35, were significantly more common in patients with generalized GA compared to healthy controls, though this association did not hold for the localized form.11PubMed. A study of HLA antigen association in localized and generalized granuloma annulare HLA genes encode proteins that present pieces of molecules to T cells, essentially deciding what the immune system reacts to. Variations in HLA genes are among the strongest genetic risk factors for autoimmune diseases across the board, from type 1 diabetes to celiac disease.
Familial cases add another dimension. A report documented GA occurring in both a father and his daughter and confirmed that both carried the HLA-B35 variant. A review of other familial cases found that monozygotic twins with GA both carried a genetic haplotype associated with a TNF-α polymorphism that leads to increased TNF-α production.12PubMed Central. Familial granuloma annulare: First report of occurrence in a father and daughter and updated review of the literature TNF-α is one of the same inflammatory cytokines identified in GA lesion profiling, so the genetic predisposition and the tissue-level inflammation converge on the same molecular players.
Localized Versus Generalized Forms
GA is not a single uniform condition, and this matters for the autoimmune question. Localized GA, which appears as one or a few ring-shaped patches usually on the hands, feet, or elbows, is the most common form and tends to behave differently from generalized GA, where lesions are widespread across the body.
Localized GA is frequently self-limited and can resolve on its own without treatment.13PubMed Central. Granuloma Annulare: An Updated Review of Epidemiology, Pathogenesis, and Treatment Options It often appears in otherwise healthy children and young adults, and its connection to systemic autoimmune disease is weaker. Generalized GA, by contrast, is more stubborn, more likely to be associated with metabolic and autoimmune conditions, and more likely to carry the HLA-B35 genetic marker. A retrospective review of 407 patients found that generalized GA had significantly higher rates of diabetes and dyslipidemia compared to localized GA, with dyslipidemia more than doubling the odds of having the generalized form.14PubMed Central. Localized Versus Generalized Granuloma Annulare: A Retrospective Review of 407 Patients
This distinction suggests that generalized GA may represent a more systemically immune-driven process, while localized GA could be triggered by more local factors like minor trauma or insect bites. The two forms likely share core mechanisms but differ in the degree to which systemic immune dysregulation is involved.
Why It Has Not Been Officially Labeled Autoimmune
Given all this immune involvement, you might wonder why GA is still described in many textbooks and dermatology references as a condition “of unknown etiology” rather than a recognized autoimmune disease. Several reasons account for the hesitation.
First, no specific autoantigen has been identified in GA. In classic autoimmune diseases, the immune system targets a particular self-protein: thyroid peroxidase in Hashimoto’s thyroiditis, for instance, or double-stranded DNA in lupus. In GA, the immune system is clearly activated and causing tissue damage, but researchers have not pinpointed exactly what it is reacting against. The broad T-cell receptor usage found in GA lesions suggests the attack is not narrowly focused on one molecule, which makes it harder to call it autoimmune in the strictest sense.
Second, GA can resolve spontaneously, especially the localized form. Most autoimmune diseases are chronic and progressive without treatment. The self-limiting nature of localized GA complicates the picture, though it is worth noting that some autoimmune conditions do wax and wane, and generalized GA rarely resolves on its own.
Third, the associations with diabetes and hyperlipidemia muddy the waters. These are metabolic conditions, not autoimmune ones (type 2 diabetes, which is the type linked to GA, is metabolic, distinct from autoimmune type 1 diabetes). Some researchers have suggested that metabolic inflammation, a chronic low-grade immune activation driven by obesity and insulin resistance, might contribute to GA through a mechanism that is inflammatory but not strictly autoimmune.
The most accurate current framing is that GA is an immune-mediated granulomatous disease with autoimmune features. It shares pathways, comorbidities, and genetic risk factors with autoimmune diseases, but it has not yet satisfied the full checklist that immunologists typically require for that label.
Treatments That Target the Immune System Are Working
Perhaps the most practical evidence that GA is immune-driven comes from treatment responses. If blocking specific immune pathways makes GA go away, that tells you those pathways were causing it.
JAK inhibitors, drugs originally developed for rheumatoid arthritis and other autoimmune conditions, have shown striking results in GA. A systematic review found that across reported cases, clinical improvement was seen in every patient treated with JAK inhibitors, with complete clearance in 58% and partial or near-complete response in the remaining 42%.15PubMed Central. Treatment of Generalized Granuloma Annulare with JAK Inhibitors: Systematic Review Most of these patients had failed multiple previous treatments, making the response rate especially noteworthy. This tracks with the molecular finding that JAK-STAT signaling is constitutively activated in GA skin.
Biologic drugs targeting specific immune molecules have also shown promise. A case series evaluating several biologics and oral JAK inhibitors found that adalimumab, which blocks TNF-α, led to marked response or remission in about 64% of patients. Dupilumab, which targets Th2 cytokines, produced moderate or better responses in about 63% of patients. Upadacitinib, a selective JAK inhibitor, produced a positive response in all five patients treated, with 80% achieving marked response or remission.16Journal of Drugs in Dermatology. Treatment of Generalized Granuloma Annulare With Biologics and Oral JAK Inhibitors: A Case Series The fact that drugs designed to suppress autoimmune inflammation also suppress GA is strong functional evidence that the same kind of immune dysfunction underlies both.
Conditions That Can Look Like GA
Part of the confusion around GA and autoimmunity stems from the fact that GA can be tricky to diagnose. It can resemble other granulomatous conditions that have clearer autoimmune or infectious causes, including sarcoidosis and necrobiosis lipoidica (a skin condition strongly associated with diabetes). All three involve granulomas in the skin, but the patterns of tissue damage differ.
Research into tissue markers has identified ways to distinguish them. A study using the protein adipophilin found that each condition produces a distinct staining pattern: necrobiosis lipoidica shows adipophilin in zones of damaged collagen outside cells, GA shows it both inside and outside the histiocytes that form the granuloma, and sarcoidosis shows it clustered inside histiocytes.17PubMed. Adipophilin expression in necrobiosis lipoidica, granuloma annulare, and sarcoidosis GA has also been reported rarely in association with solid organ cancers, where it appears as a paraneoplastic phenomenon, meaning the cancer triggers an immune response that manifests as skin lesions.18Journal of the American Academy of Dermatology. Paraneoplastic granuloma annulare: A case-matched retrospective review These cases are rare, but they reinforce the idea that GA is fundamentally a disorder of immune regulation that can be set off by different upstream causes.
What This Means If You Have GA
If you have been diagnosed with GA, the autoimmune question is not purely academic. The association with autoimmune thyroiditis and other autoimmune conditions means it may be worth having your thyroid function and basic metabolic markers checked, especially if your GA is the generalized type. The JAMA Dermatology population study found that the link to both diabetes and autoimmune conditions was statistically robust across a large cohort, so screening is a reasonable conversation to have with your doctor.6PubMed Central. Association of Granuloma Annulare With Type 2 Diabetes, Hyperlipidemia, Autoimmune Disorders, and Hematologic Malignant Neoplasms
For treatment, the emerging success of JAK inhibitors and biologics is reshaping options for people with stubborn generalized GA that does not respond to topical steroids or other first-line approaches. These drugs are still used off-label for GA in most settings, and they carry their own risks, but the response rates reported so far are encouraging for a condition that has historically been difficult to treat once it becomes widespread. As the molecular understanding of GA continues to sharpen, the treatments are likely to become more targeted, and the autoimmune question may finally get a definitive answer rather than the current educated hedge.